Desvenlafaxine Tablet, Extended Release
Product Images NDC 50090-5274

7 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 50090-5274). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

Figure 1 (Desvenlafaxine Figure1)
A pharmacokinetic (PK) chart showing geometric mean ratios with 90% confidence intervals for Cmax and AUC comparing Desvenlafaxine extended release tablet across groups with varying renal and hepatic impairment and population demographics, including gender and age groups, relative to a reference.*
FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

Figure 2 (Desvenlafaxine Figure2)
A pharmacokinetic plot showing geometric mean ratios with 90% confidence intervals for Cmax and AUC changes relative to reference when Desvenlafaxine is co-administered with the CYP3A4 inhibitor ketoconazole. The horizontal axis depicts change relative to reference ranging from 0.5 to 2.0.*
FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

Figure 3 (Desvenlafaxine Figure3)
A forest plot chart presenting the geometric mean ratio (90% confidence interval) of pharmacokinetic parameters (Cmax and AUC) showing interaction effects between desvenlafaxine at various doses and different CYP2D6 and CYP3A4 substrate drugs including desipramine, midazolam, tamoxifen, and aripiprazole.*
FDA Label Image

Figure 4 (Desvenlafaxine Image4)

Figure 4 (Desvenlafaxine Image4)
A line graph comparing the estimated proportion of patients with relapse (%) over time in days from randomization for Desvenlafaxine Extended-Release Tablets 50 mg and Placebo. The x-axis shows time to relapse in days, and the y-axis shows the percentage of patients relapsing up to 50%. Two lines indicate relapse rates, with the Desvenlafaxine group showing a lower relapse proportion than Placebo over the 200-day period.*
FDA Label Image

Figure 5 (Desvenlafaxine Image5)

Figure 5 (Desvenlafaxine Image5)
A Kaplan-Meier curve graph showing the estimated proportion of patients with relapse (%) over time in days from randomization. The graph compares Desvenlafaxine Extended-Release Tablets and Placebo groups, illustrating time to relapse differences between the treatments.*
FDA Label Image

Structure (Desvenlafaxine Structure1)

Structure (Desvenlafaxine Structure1)
Chemical structure of Desvenlafaxine Succinate, showing the molecular arrangement with phenol, cyclohexanol, and succinate components along with the hydrate form.*
FDA Label Image

Label Image (Lbl500905274)

Label Image (Lbl500905274)
Desvenlafaxine 25 mg extended release tablets label from A-S Medication Solutions. The label identifies the dosage form as film-coated, extended-release tablets containing desvenlafaxine succinate. It provides storage instructions to keep the product at 68 to 77 degrees Fahrenheit and indicates a package count of 30 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.